About: Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin
Creator	Wang, Tian Gallelli, Luca Fu, Fenghua Zhang, Leiming
Source	Medline; PMC
abstract	Acute lung injury (ALI) represents the most severe form of the viral infection sustained by coronavirus disease 2019 (COVID‐19). Today, it is a pandemic infection, and even if several compounds are used as curative or supportive treatment, there is not a definitive treatment. In particular, antiviral treatment used for the treatment of several viral infections (eg, hepatitis C, HIV, Ebola, severe acute respiratory syndrome–coronavirus) are today used with a mild or moderate effect on the lung injury. In fact, ALI seems to be related to the inflammatory burst and release of proinflammatory mediators that induce intra‐alveolar fibrin accumulation that reduces the gas exchange. Therefore, an add‐on therapy with drugs able to reduce inflammation, edema, and cell activation has been proposed as well as a treatment with interferon, corticosteroids or monoclonal antibodies (eg, tocilizumab). In this article reviewing literature data related to the use of escin, an agent having potent anti‐inflammatory and anti‐viral effects in lung injury, we suggest that it could represent a therapeutic opportunity as add‐on therapy in ALI related to COVID‐19 infection.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1002/jcph.1644
bibo:pmid	32441805
has license	no-cc
sha1sum (hex)	37ae076f156f037431147a259aad7f31b92998ab
schema:url	https://doi.org/10.1002/jcph.1644
resource representing a document's title	Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin
has PubMed Central identifier	PMC7280635
has PubMed identifier	32441805
schema:publication	J Clin Pharmacol
resource representing a document's body	covid:37ae076f156f037431147a259aad7f31b92998ab#body_text
is schema:about of	named entity 'effects' named entity 'lung injury' named entity 'severe' named entity 'hepatitis C' named entity 'moderate' named entity 'anti-viral' named entity 'Infection' named entity 'INFECTION' named entity 'PARTICULAR' named entity 'CURATIVE' named entity 'Acute lung injury' named entity 'drugs' named entity 'activation' named entity 'respiratory' named entity 'fibrin' named entity 'cell' named entity 'TNF-α' named entity 'clinical symptoms' named entity 'immune cell' named entity 'escin' named entity 'plasma levels' named entity 'remdesivir' named entity 'antiviral drugs' named entity 'ALI' named entity 'inflammation' named entity 'antiinflammatory' named entity 'tocilizumab' named entity 'Ebola' named entity 'ALI' named entity 'monoclonal antibodies' named entity 'COVID' named entity 'supportive treatment' named entity 'anti-viral' named entity 'edema' named entity 'alveolar' named entity 'gas exchange' named entity 'lung injury' named entity 'infection' named entity 'antiviral treatment' named entity 'viral infections' named entity 'lung injury' named entity 'HIV' named entity 'Infection' named entity 'antiviral therapy' named entity 'IL-1β' named entity 'TNF-α' named entity 'COVID' named entity 'inflammation' named entity 'antiviral' named entity 'arbidol' named entity 'drug discovery' named entity 'COVID' named entity 'clinical trials' named entity 'Toll-like receptor 4' named entity 'TNF' named entity 'macrophage' named entity 'China' named entity 'Dengue virus' named entity 'ribavirin' named entity 'proinflammatory' named entity 'proinflammatory' named entity 'fibrin' named entity 'endothelial cells' named entity 'minimally invasive' named entity 'Clinical trials' named entity 'COVID-19' named entity 'ALI' named entity 'granulocyte colony-stimulating factor' named entity 'exudates' named entity 'acute exacerbation' named entity 'velpatasvir' named entity 'anti-inflammatory effect' named entity 'leukocytes' named entity 'hydroxychloroquine sulfate' named entity 'vascular permeability' named entity 'Escin' named entity 'RSV' named entity 'macrophage inflammatory protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software